Biogen files with FDA for approval of Alzheimer's therapy
Biogen has requested priority review for Alzheimer's disease therapy aducanumab, which could speed the medication's path to market.
By Timothy Annett, Bloomberg
Biogen said it had submitted an application seeking U.S. approval for its Alzheimer's disease therapy aducanumab, which could become one of the first medicines of its kind to be made available to treat the memory-wasting disease.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
